Key points from article :
Adicet Bio has struck a deal to merge with resTORbio, bagging itself a Nasdaq listing.
The deal will see Adicet land a spot on Nasdaq without going the IPO route.
Investment will fund development of a cell therapy pipeline led by anti-CD20 prospect ADI-001.
The combined company will take Adicet’s name and focus on its pipeline.
It will be led by resTORbio CEO Chen Schor.
Shareholders in Adicet will own 75% of the combined company.
IND-enabling activities in support of ADI-001 are underway.
Phase 1 trial underway, expected to deliver clinical data next year.
To reveal whether the tumor control Adicet saw in mice translates into humans.
And to validate Adicet’s belief it has a differentiated, off-the-shelf cell therapy platform.
